Home | Contact Us | Site Map
Tinea capitis

Development Plan:

NanoBio's NanoStat™ product formulation for the treatment of tinea capitis has demonstrated fungicidal activity against a large range of dermatophytes to include those most commonly indicated in tinea capitis

The product has shown a remarkable safety profile in numerous human and animal studies.  NanoBio expects to announce plans in 2009 to begin a Phase 2 study.

Mechanism of Action

About tinea capitis:

Tinea capitis is a disease caused by superficial fungal infection of the skin of the scalp, eyebrows, and eyelashes, with a propensity for attacking hair shafts and follicles. The disease is considered to be a form of superficial mycosis or dermatophytosis.  Several synonyms are used, including ringworm of the scalp and tinea tonsurans. In the United States and other regions of the world, the incidence of tinea capitis is increasing. 

There are currently no effective topicals available for the treatment of tinea capitis.

Systemic administration of itraconazole and terbinafine are used most commonly for the treatment of tinea capitis.  The potential for side effects with systemic antifungals is a special concern considering that the majority of patients are preadolescent children.

BlueLine

© NanoBio® Corporation 2010
NanoBio is a registered trademark of NanoBio Corporation.
All other company, brand, and product names are or may be trademarks of their respective holders. Website by Mellon & Associates, LLC.